Extended follow-up shows continued benefit of nivolumab

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 17 / Springer Healthcare

Extended follow-up shows continued benefit of nivolumab–ipilimumab in mesothelioma

Oncology Lung Cancer ESMO-2021

Description

Stephen Liu provides an independent comment on the 3-year update of the CheckMate 743 trial of dual checkpoint blockade with nivolumab plus ipilimumab in people with inoperable malignant pleural mesothelioma.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.